SCHEMBL3063403

SCHEMBL3063403

Nc1cnc(-c2ccncc2Cl)c(Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.44
LIMK1 P53667 2/20 0.41
IDO1 P14902 1/20 0.40
SCN2A Q99250 1/20 0.40
ADORA2B P29275 2/20 0.38
NFATC1 O95644 1/20 0.37
GSK3B P49841 1/20 0.37
DYRK1A Q13627 1/20 0.37
CDC25B P30305 1/20 0.37
ADORA2A P29274 2/20 0.35
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
NQO2 P16083 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
KCNH2 Q12809 1/20 0.35
AOC3 Q16853 1/20 0.35
LATS1 O95835 3/20 0.35
HSP90AA1 P07900 1/20 0.34
IMPDH2 P12268 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3064624 0.84 NUDT1 (0.43) GAALIMK1SCN2AADORA2BCDC25B
SCHEMBL4694199 0.81 GAA (0.42) GAALIMK1IDO1SCN2AADORA2B
SCHEMBL14545378 0.80 ADORA2A (0.45) GAALIMK1SCN2AADORA2BADORA2A
SCHEMBL3063962 0.79 ADORA2B (0.57) LIMK1ADORA2BADORA2ANQO2CNR1
SCHEMBL3063909 0.77 ADORA2A (0.43) SCN2AADORA2BADORA2ANQO2HSP90AA1
SCHEMBL4690211 0.75 CNR1 (0.60) ADORA2BADORA2ANQO2CNR1CNR2
SCHEMBL3077195 0.74 ADORA2A (0.45) ADORA2BADORA2ANQO2
SCHEMBL4693972 0.72 GAA (0.47) GAALIMK1IDO1ADORA2BNFATC1
SCHEMBL31301252 0.71 GSK3B (0.59) GAALIMK1IDO1NFATC1GSK3B
SCHEMBL1975440 0.69 GAA (0.47) GAALIMK1ADORA2BNFATC1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
CN-101268064-A Pyrazine derivatives useful as adenosine receptor antagonists ALMIRALL LAB (ES) 2008-09-17 CN disclosed
EP-1922313-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS Laboratorios Almirall, S.A. (ES) 2008-05-21 EP disclosed
WO-2007017096-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2007-02-15 WO disclosed
WO-2007017096-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA3 GAA 3452/4885LIMK1 4566/4885IDO1 1101/4885
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS ADORA2B, ADORA2A, ADORA1 GAA 4594/4885LIMK1 4608/4885IDO1 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.